• Vertex Pharmaceuticals’ povetacicept met primary and secondary endpoints in Phase 3 RAINIER, reducing proteinuria versus placebo in IgA nephropathy.
• Results were published in the New England Journal of Medicine and presented at American Society of Nephrology Kidney Week 2026.
• The interim analysis showed favorable safety with at-home dosing every four weeks.
• Povetacicept has a November 30 PDUFA target action date.
• A new Phase 3b PAVANT study is underway to assess patient experience with povetacicept administered by autoinjector in adults with IgA nephropathy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20261023342443) on October 23, 2026, and is solely responsible for the information contained therein.